Opko Health, Inc. (OPK): Cost of Revenue
$400.94M
Year ended 2025-12-31
$348.20M
Trailing 12 months to 2026-06-30
-17.6%
3-year compound annual growth
+7.6%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $400.94M | -18.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $494.63M | -9.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $545.37M | -23.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $715.98M | n/a | 2025-03-03, From 2022-01-01 |
| No annual figure between 2016-12-31 and 2022-12-31. | |||
| 2016-12-31 | $564.10M | +191.8% | 2017-03-01, From 2016-01-01 |
| 2015-12-31 | $193.31M | n/m | 2017-03-01, From 2015-01-01 |
| 2014-12-31 | $9.37M | -10.0% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $10.42M | -62.6% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $27.88M | +61.7% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $17.24M | +27.8% | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | $13.49M | +369.2% | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | $2.88M | n/a | 2012-03-15, From 2009-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Opko Health, Inc. (OPK) | 2025-12-31 | $400.94M | -18.9% |
| Insmed Inc (INSM) | 2025-12-31 | $122.94M | +43.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $100.71M | +161.7% |
| Organogenesis Holdings Inc. (ORGO) | 2024-12-31 | $115.74M | +8.7% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $336.35M | -3.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.67M | +27.5% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
Compare OPK, INSM, TGTX, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗